# Phase 2 Head and Neck Neoplasms trials recruiting: 98 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 98 trials in phase 2 for Head and Neck Neoplasms that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Head and Neck Neoplasms trials: 98 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 4 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/head-and-neck-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 98
- Recruiting or not yet: 98
- Read on: November 19, 2026

## Trials

The 25 newest of 98, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07932067 | Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate-Risk Head and Neck Cancer | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Head and Neck Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07932067) |
| November 5, 2026 | NCT07919457 | Phenotype-based Model for Managing Chronic Post-treatment Pain Among Head and Neck Cancer Survivors: a Pilot Study | Shaukat Khanum Memorial Cancer Hospital & Research Centre | Phase 2 | Recruiting | Chronic Postsurgical Pain, Chronic Post Cancer Surgery Pain, Chronic Post Operative Pain, Radiation Effects... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919457) |
| November 5, 2026 | NCT07919444 | Effectiveness of Phenotype-based Pain Management Guidelines for Head and Neck Cancer Related Pain: a Pilot Study | Shaukat Khanum Memorial Cancer Hospital & Research Centre | Phase 2 | Recruiting | Cancer Pain, Orofacial Pain, Head and Neck Cancer, Head and Neck (HNSCC) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919444) |
| October 20, 2026 | NCT07882888 | Iparomlimab and Tuvonralimab With With Cetuximab in Resectable OSCC | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 2 | Recruiting | Head and Neck Cancer | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882888) |
| October 5, 2026 | NCT07856719 | A Ph2, Colchicine For Inflammatory Carotid Injury And Disease Evolution After Radiotherapy | M.D. Anderson Cancer Center | Phase 2 | Not yet recruiting | Head and Neck Cancer | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856719) |
| September 25, 2026 | NCT07840456 | Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial | University Hospital, Basel, Switzerland | Phase 2 | Not yet recruiting | Carcinoma, Squamous Cell of Head and Neck HNSCC | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840456) |
| September 15, 2026 | NCT07821242 | Nimotuzumab Plus Radiotherapy in Elderly Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Head & Neck Cancer, Radiotherapy | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821242) |
| September 8, 2026 | NCT07807163 | A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC | Bicara Therapeutics | Phase 2 | Recruiting | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807163) |
| August 31, 2026 | NCT07796126 | Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status | Barbara Ann Karmanos Cancer Institute | Phase 2 | Not yet recruiting | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796126) |
| August 31, 2026 | NCT07795034 | To Evaluate the Efficacy and Safety of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) Combined With NBB-001 and NBB-002 for... | Neuboron Bio-SciTech Co., Ltd. | Phase 2 | Recruiting | Head and Neck Cancer | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07795034) |
| August 24, 2026 | NCT07780877 | Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer | Fudan University | Phase 2 | Not yet recruiting | Head & Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780877) |
| August 18, 2026 | NCT07770100 | Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) | Sponsor not shown (see the record) | Phase 2 | Recruiting | Head and Neck Cancer, Non-Small Cell Lung Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer (GC) | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770100) |
| August 17, 2026 | NCT07766889 | Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Oral Squamous Cell Carcinoma, Head and Neck Cancer, Locally Advanced Head and Neck Cancer, Neoadjuvant Therapy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07766889) |
| August 10, 2026 | NCT07755449 | CLEAR (Cervical Lymphatic Exclusion in Adjuvant Radiation) | Institut Català d'Oncologia | Phase 2 | Recruiting | Locally Advanced Head and Neck Squamous Cell Carcinoma | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07755449) |
| August 7, 2026 | NCT07752394 | Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma | Tang-Du Hospital | Phase 2 | Not yet recruiting | Head & Neck Cancer | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752394) |
| July 29, 2026 | NCT07732634 | Phase 2 Study of RiMO-301 for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer | University of Illinois Chicago | Phase 2 | Recruiting | Head and Neck Cancer, Head Cancer, Neck Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07732634) |
| July 15, 2026 | NCT07704372 | Superoxide Dismutase Skin Spray for the Prevention of Acute Radiation Dermatitis in Head and Neck Cancer | West China Hospital | Phase 2 | Recruiting | Radiation-induced Dermatitis | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07704372) |
| July 9, 2026 | NCT07692997 | Sancai Fengsui Decoction for RTOM: A Multicenter RCT | Nanfang Hospital, Southern Medical University | Phase 2 | Not yet recruiting | Radiation-Induced Oral Mucositis (RTOM), Head and Neck Cancer, Oral Mucositis of RTOG Grade Greater Than 1 | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07692997) |
| June 23, 2026 | NCT07662746 | Efficacy and Safety of Paclitaxel Polymeric Micelles in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 2 | Recruiting | Head and Neck Cancer | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662746) |
| June 22, 2026 | NCT07659678 | CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma | Washington University School of Medicine | Phase 2 | Recruiting | Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Head... | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07659678) |
| June 8, 2026 | NCT07632339 | Becotatug Vedotin Combined With Pucotenlimab for Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 2 | Recruiting | Head and Neck Cancer | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07632339) |
| June 8, 2026 | NCT07631884 | Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Solid Tumors, Neoplasms (Cancer / Tumors), Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631884) |
| June 8, 2026 | NCT07631871 | An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Neoplasms, Solid Tumors, HER2 Positive Solid Tumor, Endometrial Neoplasm, Urothelial Carcinoma (UC), Pancreatic... | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631871) |
| June 8, 2026 | NCT07631650 | Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients | Sponsor not shown (see the record) | Phase 2 | Recruiting | Head and Neck Disorder, Head and Neck Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631650) |
| June 5, 2026 | NCT07630168 | Effects of Infusion Timing on Treatment Response in Solid Tumors | UNC Lineberger Comprehensive Cancer Center | Phase 2 | Recruiting | Lung Cancer, Non-small Cell Lung Cancer, Metastatic Lung Cancer, Head and Neck Cancer, Metastatic Squamous Cell... | 238 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07630168) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 4 |
| University of Chicago | 3 |
| M.D. Anderson Cancer Center | 3 |
| UNC Lineberger Comprehensive Cancer Center | 3 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 3 |
| Dana-Farber Cancer Institute | 3 |
| University of Maryland, Baltimore | 2 |
| University of Texas Southwestern Medical Center | 2 |
| Sir Mortimer B. Davis - Jewish General Hospital | 2 |
| Shaukat Khanum Memorial Cancer Hospital & Research Centre | 2 |
| Beijing Tongren Hospital | 2 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2 |
| Tang-Du Hospital | 2 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2 |
| University of California, Irvine | 2 |
| Sun Yat-sen University | 2 |
| UNICANCER | 1 |
| Rutgers, The State University of New Jersey | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| University of Zurich | 1 |
| Bicara Therapeutics | 1 |
| Centre Paul Strauss | 1 |
| University Medical Center Groningen | 1 |
| University of Oklahoma | 1 |
| University of Alabama at Birmingham | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 41 |
| China | 26 |
| France | 5 |
| Canada | 5 |
| Australia | 4 |
| Switzerland | 3 |
| Germany | 3 |
| Italy | 3 |
| Netherlands | 2 |
| Taiwan | 2 |
| Pakistan | 2 |
| Belgium | 2 |
| Spain | 2 |
| Egypt | 1 |
| Hungary | 1 |
| Japan | 1 |
| Norway | 1 |
| South Korea | 1 |
| United Kingdom | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Jewelry and watches manufacturers in the United States](https://specstream.ai/data/businesses/jewelry-and-watches-manufacturers/united-states)
- [Cardiology practices in the United States](https://specstream.ai/data/businesses/cardiology-practices/united-states)
- [Shipping and delivery companies in the United States](https://specstream.ai/data/businesses/shipping-and-delivery-companies/united-states)
- [Hostels in the United States](https://specstream.ai/data/businesses/hostels/united-states)
- [Barbecue restaurants in the United States](https://specstream.ai/data/businesses/barbecue-restaurants/united-states)
- [Public relations firms in the United States](https://specstream.ai/data/businesses/public-relations-firms/united-states)
